Northern Trust’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-738,440
| Closed | -$29.7M | – | 4448 |
|
|
2026
Q1 | $29.7M | Buy |
738,440
+41,919
| +6% | +$903K | ﹤0.01% | 1440 |
|
|
2025
Q4 | $17.5M | Buy |
696,521
+147,273
| +27% | +$3.46M | ﹤0.01% | 1760 |
|
|
2025
Q3 | $12.4M | Buy |
549,248
+23,366
| +4% | +$545K | ﹤0.01% | 1987 |
|
|
2025
Q2 | $9.1M | Buy |
525,882
+7,188
| +1% | +$133K | ﹤0.01% | 2129 |
|
|
2025
Q1 | $11.3M | Sell |
518,694
-28,582
| -5% | -$790K | ﹤0.01% | 1966 |
|
|
2024
Q4 | $17.5M | Buy |
547,276
+94,174
| +21% | +$2.83M | ﹤0.01% | 1781 |
|
|
2024
Q3 | $13.1M | Sell |
453,102
-9,116
| -2% | -$338K | ﹤0.01% | 1910 |
|
|
2024
Q2 | $17.7M | Buy |
462,218
+21,762
| +5% | +$986K | ﹤0.01% | 1628 |
|
|
2024
Q1 | $25.9M | Sell |
440,456
-8,270
| -2% | -$527K | ﹤0.01% | 1411 |
|
|
2023
Q4 | $26.9M | Sell |
448,726
-1,704
| -0.4% | -$86.4K | ﹤0.01% | 1407 |
|
|
2023
Q3 | $17.1M | Sell |
450,430
-401,842
| -47% | -$17.7M | ﹤0.01% | 1657 |
|
|
2023
Q2 | $77.6M | Sell |
852,272
-16,916
| -2% | -$1.46M | 0.01% | 692 |
|
|
2023
Q1 | $57.3M | Buy |
869,188
+12,067
| +1% | +$696K | 0.01% | 867 |
|
|
2022
Q4 | $44.3M | Buy |
857,121
+7,933
| +0.9% | +$421K | 0.01% | 993 |
|
|
2022
Q3 | $58M | Buy |
849,188
+16,490
| +2% | +$976K | 0.01% | 775 |
|
|
2022
Q2 | $37.7M | Buy |
832,698
+67,496
| +9% | +$3.08M | 0.01% | 1075 |
|
|
2022
Q1 | $38.9M | Buy |
765,202
+21,335
| +3% | +$942K | 0.01% | 1209 |
|
|
2021
Q4 | $35.2M | Buy |
743,867
+81,181
| +12% | +$3.2M | 0.01% | 1367 |
|
|
2021
Q3 | $21.8M | Sell |
662,686
-11,811
| -2% | -$664K | ﹤0.01% | 1737 |
|
|
2021
Q2 | $42.6M | Buy |
674,497
+10,173
| +2% | +$525K | 0.01% | 1262 |
|
|
2021
Q1 | $28.5M | Sell |
664,324
-23,860
| -3% | -$1.13M | 0.01% | 1571 |
|
|
2020
Q4 | $39.4M | Sell |
688,184
-17,976
| -3% | -$760K | 0.01% | 1266 |
|
|
2020
Q3 | $21.3M | Buy |
706,160
+8,276
| +1% | +$247K | ﹤0.01% | 1585 |
|
|
2020
Q2 | $22.8M | Buy |
697,884
+13,015
| +2% | +$418K | 0.01% | 1507 |
|
|
2020
Q1 | $18.3M | Buy |
684,869
+105,867
| +18% | +$3.76M | 0.01% | 1462 |
|
|
2019
Q4 | $17.7M | Sell |
579,002
-12,398
| -2% | -$343K | ﹤0.01% | 1813 |
|
|
2019
Q3 | $14.2M | Buy |
591,400
+122,868
| +26% | +$3.38M | ﹤0.01% | 1921 |
|
|
2019
Q2 | $11.9M | Buy |
468,532
+28,500
| +6% | +$580K | ﹤0.01% | 2047 |
|
|
2019
Q1 | $8.58M | Buy |
440,032
+4,304
| +1% | +$67.7K | ﹤0.01% | 2248 |
|
|
2018
Q4 | $5.75M | Sell |
435,728
-5,938
| -1% | -$91.1K | ﹤0.01% | 2416 |
|
|
2018
Q3 | $7.85M | Buy |
441,666
+14,637
| +3% | +$271K | ﹤0.01% | 2409 |
|
|
2018
Q2 | $9.39M | Buy |
427,029
+307,586
| +258% | +$7.07M | ﹤0.01% | 2306 |
|
|
2018
Q1 | $2.64M | Buy |
119,443
+4,316
| +4% | +$84.8K | ﹤0.01% | 2961 |
|
|
2017
Q4 | $2.5M | Buy |
+115,127
| New | +$1.69M | ﹤0.01% | 3010 |
|
Other funds holding APLS
Northern Trust's APLS Position: Q2 2026 in Review
Northern Trust sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 738,440 shares — an estimated $29.7M sold.
Northern Trust first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $77.6M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Northern Trust reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Northern Trust sold 738,440 Apellis Pharmaceuticals shares in Q2 2026, an estimated $29.7M.
- Northern Trust first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- Northern Trust's Apellis Pharmaceuticals position peaked at $77.6M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.